How many types of treatments are available for non-Hodgkin’s lymphoma? There are two main types of lymphoma: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Hodgkin’s lymphoma accounts for only a small percentage of patients, and most patients have non-Hodgkin’s lymphoma. The main treatment modalities for non-Hodgkin’s lymphoma are chemotherapy, targeted therapy, radiation therapy, immunotherapy, etc. Chemotherapy is the first-line treatment for non-Hodgkin’s lymphoma. Do all patients with non-Hodgkin’s lymphoma need chemotherapy? It mainly depends on the indications for chemotherapy. Based on the growth rate of the tumor, non-Hodgkin’s lymphoma can be classified as highly aggressive, aggressive and inert lymphoma. Inert gold lymphoma is a lymphoma that grows very slowly and is relatively insensitive to chemotherapy. Early inert lymphomas, such as follicular lymphoma stage I and marginal zone lymphoma, are inert lymphomas that develop very slowly. After surgical removal of tumor lesions in these patients, they can wait for observation and regular follow-up without chemotherapy. Some patients with advanced inert lymphoma can also wait for observation if they have no symptoms, while the rest of patients can basically be treated with chemotherapy. Do patients need to have any tests before chemotherapy? First of all, pathology and PET-CT are required. pathology can confirm the specific lymphoma staging and PET-CT can detect microscopic lesions throughout the body. The patient’s heart function, liver and kidney function, and bone marrow status will also need to be evaluated to determine if the bone marrow is affected. How do the tests affect the development of chemotherapy regimens? These tests can be very helpful in developing a chemotherapy regimen. Lymphoma now has more than 70 subtypes, each treated according to a separate disease. Individualized chemotherapy regimens are very important, and physicians need to select different treatments for patients depending on the nature of their pathology. If the liver and kidney function is not good, we need to combine liver and kidney protecting drugs; if the heart function is not good, we will avoid drugs that affect the heart or add heart protecting drugs. The evaluation before chemotherapy includes pathological examination and the patient’s own status, which is very important for the formulation of chemotherapy regimen, the selection of drug type and dose. When should a patient start chemotherapy? Is it started immediately after the disease is diagnosed or can it wait for some time? For inert lymphoma, especially early stage lymphoma, it is perfectly fine to observe and wait, not necessarily to actively chemotherapy. For aggressive lymphoma, such as diffuse large B-cell lymphoma, treatment should be started as soon as possible after taking a biopsy to determine the pathology. Because aggressive lymphoma patients progress very rapidly, early first-line treatment is necessary to completely control the disease and for patients to have hope for a cure.